Speaking exclusively to PharmaBoardroom, Sanofi Genzyme Executive VP Bill Sibold outlines Sanofi’s strategy for its specialty care unit, the wealth of potential breakthrough assets in its pipeline, product launch strategies, and the post-COVID industry of tomorrow.
Since I joined in 2011, it feels as if my time with Sanofi Genzyme has been one constant, giant launch! ...the fundamental challenge but also opportunity in specialty care is the need to understand the challenges and priorities of the individual patient and physician communities
